Gastric Cancer Market on Track for Strong Growth, Estimated to Grow at 15% CAGR Through 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Gastric Cancer Market Through 2025?
The scope of the gastric cancer market has expanded substantially over the past few years, projected to increase from $3.17 billion in 2024 up to $3.64 billion by 2025, reflecting a compound annual growth rate (CAGR) of 14.8%. This historical expansion phase is fundamentally linked to several factors, encompassing the increase in the elderly demographic, heightened consciousness regarding medical care, a proliferation of genetic alterations, the heightened prevalence of detrimental lifestyle choices, and a growing recognition of oncological conditions.

What's the Projected Size of the Global Gastric Cancer Market by 2029?
Anticipation surrounds the gastric cancer sector, projecting substantial escalation in its valuation across forthcoming years, culminating in a market size of $6.37 billion by 2029, fueled by a compound annual growth rate (CAGR) reaching 15.0%; this ascent during the projection window is underpinned by several factors, notably climbing rates of obesity, augmented governmental efforts, greater capital allocation toward healthcare, a heightened preference for orally administered medications, and an expansion in the total count of facilities dedicated to cancer care, while key developments expected to shape this period involve the utilization of combination chemotherapy protocols, advancements in product portfolios, the growing adoption of robotic surgical methodologies, the proliferation of targeted treatment modalities, increased strategic partnership formation, and the incorporation of cutting-edge diagnostic instruments.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

Top Growth Drivers in the Gastric Cancer Industry: What's Accelerating the Market?
Future expansion in the gastric cancer market is anticipated to be fueled by the escalating incidence of obesity, which constitutes a health disorder marked by an overaccumulation of body fat, frequently quantified by a Body Mass Index reaching 30 or above, thereby creating pathways to numerous ailments. This upward trend in obesity stems from a confluence of elements, including suboptimal dietary habits, insufficient physical movement, desk-bound existences, external environmental pressures, and inherent genetic susceptibilities. Excessive corporal adiposity, specifically the fat stored viscerally around the midsection, correlates directly with an increased probability of gastric cancer development because obesity initiates persistent inflammatory responses and metabolic irregularities, both implicated in oncogenesis, thereby boosting the need for therapeutic interventions for stomach cancer. Illustratively, data released in March 2024 by the World Health Organization, an international organization headquartered in Switzerland, indicated that roughly one in every eight individuals worldwide experienced obesity in 2022, alongside 2.5 billion adults aged 18 and older categorized as being overweight, which encompassed 890 million people dealing with obesity; this translates to 43% of adults being overweight and 16% residing with obesity, further showing that 37 million youngsters under five years carried excess weight, and over 390 million children and adolescents between the ages of 5 and 19 were overweight, including 160 million who were clinically obese. Consequently, the increasing prevalence of obesity serves as a primary catalyst for the growth trajectory of the gastric cancer market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

What Trends Will Shape the Gastric Cancer Market Through 2029 and Beyond?
Leading organizations within the gastric cancer sector are prioritizing the creation of highly sophisticated tools, notably companion diagnostic tests, aimed at facilitating customized patient care strategies. Such a diagnostic test serves the purpose of singling out individuals who possess the highest probability of responding favorably to a particular medication, determined by detecting specific biological markers. Illustratively, in the month of October 2024, the Swiss pharmaceutical giant F. Hoffmann-La Roche Ltd. received clearance from the U.S. Food and Drug Administration for the VENTANA CLDN18 (43-14A) RxDx Assay; this constituted the initial immunohistochemistry (IHC) companion diagnostic specifically authorized for quantifying CLDN18 protein levels in cases involving gastric and gastroesophageal junction (GEJ) adenocarcinoma. By quantifying variations of the CLDN18 protein, predominantly CLDN18.2, this diagnostic tool dictates patient suitability for receiving the targeted therapy known as VYLOY (zolbetuximab), representing a significant step forward in tailoring healthcare interventions for individuals afflicted with gastric and GEJ adenocarcinoma through the deployment of the OptiView DAB IHC Detection Kit on the BenchMark ULTRA platform.

What Are the Main Segments in the Gastric Cancer Market?
The gastric cancermarket covered in this report is segmented -

1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types
2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis
3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments
4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels

Subsegments:
1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma
2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma
3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST
4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3
5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

Which Top Companies are Driving Growth in the Gastric Cancer Market?
Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., AROG Pharmaceuticals Inc.

Which Regions Will Dominate the Gastric Cancer Market Through 2029?
North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20797

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.